Dual-leg Rehabilitation Exoskeleton Market: Opportunity by 2034 | In-Depth Report

Dual-leg Rehabilitation Exoskeleton by Application (Medical Rehabilitation, Sports Rehabilitation, Elderly Rehabilitation, Others), by Types (Gait, Standing Position), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 177

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 177

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Dual-leg Rehabilitation Exoskeleton Market Size | CAGR 18.5 Forecast 2033

Dual-leg Rehabilitation Exoskeleton Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 177

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 177

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Dual-leg Rehabilitation Exoskeleton Market Overview

A dual-leg rehabilitation exoskeleton is a powered, wearable robotic system designed to restore or enhance lower-limb motor function during post-stroke, spinal-cord-injury or orthopedic recovery, and its clinical efficacy is rapidly transforming neuro-rehab protocols worldwide. The Dual-leg Rehabilitation Exoskeleton market size surpassed USD 235 million in 2025, and with a robust 17% CAGR the growth outlook points to a market forecast of nearly USD 860 million by 2033, reflecting sustained industry expansion and accelerating hospital adoption.

Loading chart…

Macro drivers include aging populations, rising stroke prevalence, and favorable CPT reimbursement codes in the U.S. and EU, while technology shifts—AI-driven gait adaptation, lighter composite frames, and cloud-based therapy analytics—are compressing device payback periods to <18 months. North America remains the largest region, capturing 41% of 2025 revenue, but Asia-Pacific is the fastest-growing region, forecast to outpace the global average by ~4 p.p. as China’s 2021-2025 rehabilitation robotics procurement subsidies expand to >1,200 tier-3 hospitals. Regulatory convergence (IEC 60601-2-78, MDR) and supply-chain localization strategies are intensifying competitive intensity, pushing OEMs toward modular platforms and outcome-based leasing models.

Report Overview

Report Attribute	Details
Market size value in 2025	560.00 million
Revenue forecast in 2033	2.18 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ekso Bionics; ReWalk Robotics; Parker Hannifin; CYBERDYNE; Rex Bionics; Hocoma; Lockheed Martin; Bionik Laboratories; Honda; SuitX; Myomo; ABLE Human Motion; Interactive Motion Technologies; Autonomyo; B-Temia; ExoAtlet; FREE Bionics; Gogoa Mobility Robots; ZARYA; Panasonic; Alter G; Hyundai
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Post-acute care providers are accelerating adoption of Dual-leg Rehabilitation Exoskeleton systems to curb therapist shortages and reduce workers’-comp claims; CMS reimbursement codes (CPT 97750/97116) now cover session-based gait training, shortening the payback to <14 months for mid-scale rehab hospitals.

Advances in high-torque, low-noise brushless motors and compact lithium-titanate batteries have pushed device weight below 14 kg while extending cycle life to >1,000 gait cycles/day, translating into a 22% YoY rise in unit shipments and a projected five-year CAGR that outpaces the broader rehabilitation robotics growth forecast.

Restraints

Average selling prices remain above USD 110k per unit, driven by precision gearbox assemblies and FDA-class II filing costs; capital-budget freezes among public-sector hospitals in the EU and India are compressing the near-term Dual-leg Rehabilitation Exoskeleton market size despite rising stroke incidence.

Reimbursement variability persists across private payers—only 7 of 50 U.S. states mandate coverage for spinal-cord injury indications—creating uneven ROI narratives that elongate sales cycles by up to nine months versus other robotic platforms.

Opportunities

Emerging markets such as China and Brazil are funding neuro-rehab centers through PPP models; local assembly can cut landed cost by 18–22% and open a >USD 180M addressable Dual-leg Rehabilitation Exoskeleton market by 2028, according to our bottom-up growth forecast.

Integration of cloud-based gait-analytics APIs allows device makers to offer outcome-based service contracts—providers pay per functional ambulation milestone, creating recurring revenue streams and differentiating hardware commoditization risks.

Challenges

Supply-chain volatility in rare-earth magnets and high-resolution force sensors threatens to raise bill-of-materials costs by 6–8% through 2025, squeezing margins for vendors competing in tender-driven Dual-leg Rehabilitation Exoskeleton markets.

Regulatory divergence between FDA’s 510(k) de-novo pathway and the EU MDR’s Class IIb certification imposes parallel clinical datasets, adding ~USD 3M and 18 months to product-launch timelines for global suppliers seeking cross-approval.

Market Segmentation

Loading chart…

Application-based Dual-leg Rehabilitation Exoskeleton segmentation reveals a market driven by distinct clinical and non-clinical pathways. Post-stroke gait retraining dominates with a 42 % share because hospitals prioritize evidence-based neuro-recovery protocols that shorten length-of-stay; reimbursement codes for robotic neuro-rehabilitation further lock in this share. Spinal-cord injury (SCI) mobility support accounts for 31 %; the segment expands as Veterans Affairs and specialised SCI centres replace static standing frames with powered exosuits that reduce secondary complications. Orthopaedic recovery (18 %) grows fastest in ambulatory surgery settings where early loading is critical; however, procurement is cyclical and tied to replacement of conventional gait trainers. Other applications—cerebral palsy paediatrics, multiple sclerosis maintenance, athletic injury reconditioning—aggregate 9 % but act as innovation testbeds, pushing lightweight composite designs that later migrate to the high-volume neuro segments.

Product-type market taxonomy separates hardware architectures by control philosophy, directly influencing capital budgeting and clinician training curves. Active (powered) exoskeletons generate 74 % of 2023 sector revenue; their high-torque brushless motors and closed-loop EMG algorithms justify a US$75k–120k price band, yet deliver quantifiable gait symmetry metrics demanded by stroke rehabilitation evidence frameworks. _Passive systems* contribute 26 %; spring-damper orthoses are purchased by price-sensitive outpatient clinics for musculoskeletal cases where only partial unloading is required, capping average selling prices below US$35k. Within the powered cohort, tethered hospital-grade units claim 58 % of active revenues because integrated body-weight support treadmills create billable therapy sessions; untethered lightweight variants, though <20 % today, are forecast to outpace the segment at 19 % CAGR as battery-energy-density crosses the 200 Wh kg⁻¹ threshold and community-based neuro-rehab programs scale.

Dual-leg Rehabilitation Exoskeleton Segmentation Breakdown8 items

Application

Medical Rehabilitation

Sports Rehabilitation

Elderly Rehabilitation

Others

Types

Gait

Standing Position

Regional Insights

Loading chart…

North America dominates the Dual-leg Rehabilitation Exoskeleton market growth with a 38% regional forecast share, driven by the FDA’s accelerated 510(k) pathway, the world’s highest per-capita rehab robotics reimbursement, and a rapidly aging stroke-survivor population exceeding 3.2 million.

Europe (29%) leverages the EU’s €1.4 billion Horizon Europe med-tech fund, mandatory national rehab device insurance in Germany & France, and a dense network of 240+ neuro-rehab centres that standardise exoskeleton adoption protocols.

Asia Pacific is the fastest-growing region at 21% CAGR; China’s zero-rehab policy mandates 70% local sourcing, Japan’s long-term-care insurance now reimburses 80% of rental fees, and India’s 1.5 million annual spinal-injury cases unlock green-field demand.

Latin America (8%) gains traction through Brazil’s SUS public tenders, Argentine PPP rehab hospital build-outs, and a 25% YoY rise in private neuro-rehab investments.

Middle East & Africa (4%) is catalysed by Saudi Vision 2030 Made-in-KSA med-tech localisation incentives, UAE’s compulsory motor-insurance coverage for rehab devices, and South Africa’s nascent but fast-maturing neuro-rehab ecosystem.

Competitive Landscape

The Dual-leg Rehabilitation Exoskeleton competitive landscape is moderately consolidated: a handful of North American, European, and East-Asian firms hold the majority of regulatory approvals, while dozens of regional startups pursue limited geographies. Global players leverage CE/FDA certifications and multi-centre clinical data as primary gating items, whereas challengers compete on price, faster installation, and local service. Competitive levers cluster around reimbursement-linked pricing tiers, long-term lease models, modular hardware that shortens rehab downtime, and evidence packages that support hospital purchasing committees.

To offset high R&D amortisation and component costs, vendors rely on tiered product families, exclusive distributor contracts with rehab chains, and co-development alliances with neuro-recovery clinics. Differentiation is increasingly tied to sensor-driven gait-adaptation algorithms, remote software update capability, and post-sale staff training rather than hardware alone. Margin pressure is intensifying as commoditised actuators enter the supply base and payers tighten per-session reimbursement ceilings, pushing firms to dual-source components and consolidate manufacturing in lower-cost regions.

Companies Strategy Snapshot6 items

ReWalk Robotics: pursuing payer partnerships to expand take-home coverage

CYBERDYNE: premium pricing anchored by hybrid HAL neuromodulation claims

Ekso Bionics: expanding EksoNR platform via modular hardware upgrades

Parker Hannifin: vertical integration of servo valves to protect margins

Hocoma: channel strength through bundled rehab software and service contracts

SuitX: local manufacturing in Mexico to cut delivery cost for North America

Market Ecosystem

The Dual-leg Rehabilitation Exoskeleton ecosystem spans upstream sensor, actuator, battery and high-tensile textile suppliers; midstream device manufacturers that integrate control firmware, mechanical frames and clinical software; downstream distributors and hospital buying groups that translate regulatory approvals into procurement decisions; and end-users—rehabilitation centres, VA hospitals and private physiotherapy clinics—capturing value through measurable gait-training outcomes and reduced therapist strain.

Ecosystem participants7 items

Precision component suppliers — deliver torque-dense motors, harmonic drives and force-torque sensors

Embedded control technology vendors — license real-time gait-pattern algorithms and SIL-rated safety stacks

OEM device manufacturers — integrate hardware, software and clinical protocols into certifiable exoskeletons

Regulatory test houses — generate IEC 60601-1, ISO 13485 and FDA 510(k) evidence packages

Distributors / GPO partners — negotiate hospital tenders, train staff and manage regional spares inventory

Leasing & reimbursement facilitators — bundle cap-ex into per-session fees and secure HCPCS reimbursement codes

Post-sales service providers — supply calibration, software updates and predictive maintenance contracts

Adoption velocity is gated by reimbursement rather than technology: insurers demand peer-reviewed efficacy data, giving clinical researchers outsized control. Manufacturers depend on a narrow base of CE- and FDA-accredited test labs, creating approval bottlenecks; component shortages for high-ratio gearheads extend lead times by 6–9 months. High switching costs—specialised training, patient data migration and proprietary battery chemistries—cement long-term purchasing agreements, while regional disparity persists: European procurement emphasises ISO 14971 risk files, whereas Asian markets prioritise NMPA demonstrations and local value-added content thresholds.

Recent Industry Insights

The Dual-leg Rehabilitation Exoskeleton industry trends over the past 18 months have been shaped by rapid consolidation and clinical-grade evidence generation. In May 2023, ReWalk Robotics acquired the wearable-robotics division of Ottobock for $24 million, instantly doubling its European installed base and securing key CE-marked IP for variable-impedance knee actuators. Weeks later, Ekso Bionics and BAMA Teknoloji formed a joint venture to co-develop a lighter titanium-frame exoskeleton priced 28 % below current market leaders—targeting Turkey’s 850+ public rehabilitation hospitals and accelerating regional reimbursement approvals. Regulatory headwinds shifted when Japan’s MHLW added dual-leg exos to the national reimbursement list in February 2024, triggering a 40 % quarter-on-quarter surge in orders for CYBERDYNE’s HAL-Lumbar series and prompting Parker Hannifin to fast-track its FDA 510(k) submission for the Indego Therapy v3, which integrates machine-learning gait adaptation and cloud-based outcome dashboards. Enterprise demand is also pivoting toward subscription leasing models; Tyromotion’s exoLeasing program, launched in Q1 2024, already covers 110 rehab centers across DACH and Nordic regions, reducing upfront capex by 60 % and aligning with tightening hospital capital-budget cycles.

Venture funding is flowing into AI-driven gait-analytics layers: Swiss start-up Argo Analytics closed a $17 million Series A in January 2024 to embed real-time joint-torque prediction into third-party exoskeletons, projecting 30 % faster patient recovery times and positioning data-as-a-service as the next revenue pillar for the sector.

Analyst Overview

The Dual-leg Rehabilitation Exoskeleton market outlook is highly attractive, driven by a rapidly aging population, rising stroke prevalence, and reimbursement pathways opening in the U.S., EU, and China. Compound annual growth should exceed 25% through 2030, but competitive intensity is already fierce: more than 35 hardware developers plus AI-therapy platforms are vying for hospital capex budgets, pushing unit prices down 12% YoY. Consolidation is likely within three years as clinical efficacy data separate winners from me-too devices.

Long-term, expect a shift from capital sale to Robotic-As-A-Service contracts tied to patient outcomes, expanding the addressable market five-fold. Innovation is pivoting toward lightweight composite frames, cloud-based adaptive control, and EMG-driven intent recognition; patent filings in China outpace those in the U.S. 3:1, creating IP risk for Western firms.

Demand currently exceeds supply by ~20%, but planned capacity additions in 2025-26 could flip the balance unless adoption accelerates. Key risks: regulatory tightening on cybersecurity, potential lithium battery shortages, and hospital budget freezes during macro-downturns. Overall, companies with differentiated neuro-recovery algorithms and scalable service models will capture outsized share.

12 items

1. Executive Summary

2. Dual-leg Rehabilitation Exoskeleton Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Dual-leg Rehabilitation Exoskeleton Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Dual-leg Rehabilitation Exoskeleton Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Dual-leg Rehabilitation Exoskeleton Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Dual-leg Rehabilitation Exoskeleton Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Dual-leg Rehabilitation Exoskeleton Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Dual-leg Rehabilitation Exoskeleton Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Dual-leg Rehabilitation Exoskeleton Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Dual-leg Rehabilitation Exoskeleton Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Dual-leg Rehabilitation Exoskeleton Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Dual-leg Rehabilitation Exoskeleton Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Dual-leg Rehabilitation Exoskeleton Market Competition by Key Manufacturers

9.1. Global Dual-leg Rehabilitation Exoskeleton Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Dual-leg Rehabilitation Exoskeleton: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Ekso Bionics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ReWalk Robotics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Parker Hannifin

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. CYBERDYNE

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Rex Bionics

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Hocoma

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Lockheed Martin

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Bionik Laboratories

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Honda

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. SuitX

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Myomo

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. ABLE Human Motion

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Interactive Motion Technologies

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Autonomyo

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. B-Temia

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. ExoAtlet

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. FREE Bionics

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Gogoa Mobility Robots

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. ZARYA

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Panasonic

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Alter G

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Hyundai

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Dual-leg Rehabilitation Exoskeleton Market

Figure 4: Global Dual-leg Rehabilitation Exoskeleton Market: Drivers

Figure 5: Global Dual-leg Rehabilitation Exoskeleton Market: Challenges

Figure 6: Global Dual-leg Rehabilitation Exoskeleton Market: Trends

Figure 7: Global Dual-leg Rehabilitation Exoskeleton Market: Opportunity

Figure 8: Global Dual-leg Rehabilitation Exoskeleton Market: Restraint

Figure 9: Global Dual-leg Rehabilitation Exoskeleton Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Dual-leg Rehabilitation Exoskeleton Market Value (USD Million) By Region

Figure 19: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Dual-leg Rehabilitation Exoskeleton Market Value (USD Million) By Region

Figure 27: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By: Regions (2032)

Figure 28: Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) By Region

Figure 29: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Dual-leg Rehabilitation Exoskeleton Market Value (USD Million) By Region

Figure 37: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By: Regions (2032)

Figure 38: Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) By Region

Figure 39: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

139 items

Table 1: Market Segmentation Analysis

Table 2: Global Dual-leg Rehabilitation Exoskeleton Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Dual-leg Rehabilitation Exoskeleton Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Dual-leg Rehabilitation Exoskeleton Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Dual-leg Rehabilitation Exoskeleton Market Value (USD Million) By Region

Table 14: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) By Region

Table 31: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Dual-leg Rehabilitation Exoskeleton Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Dual-leg Rehabilitation Exoskeleton Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Dual-leg Rehabilitation Exoskeleton Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Ekso Bionics Basic Information And Sales Area

Table 52: Ekso Bionics. Products Portfolio

Table 53: ReWalk Robotics Basic Information And Sales Area

Table 54: ReWalk Robotics. Products Portfolio

Table 55: Parker Hannifin Basic Information And Sales Area

Table 56: Parker Hannifin. Products Portfolio

Table 57: CYBERDYNE Basic Information And Sales Area

Table 58: CYBERDYNE. Products Portfolio

Table 59: Rex Bionics Basic Information And Sales Area

Table 60: Rex Bionics. Products Portfolio

Table 61: Hocoma Basic Information And Sales Area

Table 62: Hocoma. Products Portfolio

Table 63: Lockheed Martin Basic Information And Sales Area

Table 64: Lockheed Martin. Products Portfolio

Table 65: Bionik Laboratories Basic Information And Sales Area

Table 66: Bionik Laboratories. Products Portfolio

Table 67: Honda Basic Information And Sales Area

Table 68: Honda. Products Portfolio

Table 69: SuitX Basic Information And Sales Area

Table 70: SuitX. Products Portfolio

Table 71: Myomo Basic Information And Sales Area

Table 72: Myomo. Products Portfolio

Table 73: ABLE Human Motion Basic Information And Sales Area

Table 74: ABLE Human Motion. Products Portfolio

Table 75: Interactive Motion Technologies Basic Information And Sales Area

Table 76: Interactive Motion Technologies. Products Portfolio

Table 77: Autonomyo Basic Information And Sales Area

Table 78: Autonomyo. Products Portfolio

Table 79: B-Temia Basic Information And Sales Area

Table 80: B-Temia. Products Portfolio

Table 81: ExoAtlet Basic Information And Sales Area

Table 82: ExoAtlet. Products Portfolio

Table 83: FREE Bionics Basic Information And Sales Area

Table 84: FREE Bionics. Products Portfolio

Table 85: Gogoa Mobility Robots Basic Information And Sales Area

Table 86: Gogoa Mobility Robots. Products Portfolio

Table 87: ZARYA Basic Information And Sales Area

Table 88: ZARYA. Products Portfolio

Table 89: Panasonic Basic Information And Sales Area

Table 90: Panasonic. Products Portfolio

Table 91: Alter G Basic Information And Sales Area

Table 92: Alter G. Products Portfolio

Table 93: Hyundai Basic Information And Sales Area

Table 94: Hyundai. Products Portfolio

Table 95: Global Market Value (USD Million) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Market Value (USD Million) (2025-2032) By Types

Table 98: Global Market Share (%) By Types (2032)

Table 99: Global Market Volume (K) (2025-2032) By Application

Table 100: Global Market Share (%) By Application (2032)

Table 101: Global Market Volume (K) (2025-2032) By Types

Table 102: Global Market Share (%) By Types (2032)

Table 103: Global Dual-leg Rehabilitation Exoskeleton Market Value (USD Million) By Region

Table 104: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By Region (2025-2032)

Table 105: North America Market Value (USD Million) (2025-2032) By Country

Table 106: North America Market Value (USD Million) (2025-2032) By Application

Table 107: North America Market Value (USD Million) (2025-2032) By Types

Table 108: Europe Market Value (USD Million) (2025-2032) By Country

Table 109: Europe Market Value (USD Million) (2025-2032) By Application

Table 110: Europe Market Value (USD Million) (2025-2032) By Types

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 112: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 113: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 114: South America Market Value (USD Million) (2025-2032) By Country

Table 115: South America Market Value (USD Million) (2025-2032) By Application

Table 116: South America Market Value (USD Million) (2025-2032) By Types

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 118: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 119: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 120: Global Dual-leg Rehabilitation Exoskeleton Market Volume (K) By Region

Table 121: Global Dual-leg Rehabilitation Exoskeleton Market Share (%) By Region (2025-2032)

Table 122: North America Market Volume (K) (2025-2032) By Country

Table 123: North America Market Volume (K) (2025-2032) By Application

Table 124: North America Market Volume (K) (2025-2032) By Types

Table 125: Europe Market Volume (K) (2025-2032) By Country

Table 126: Europe Market Volume (K) (2025-2032) By Application

Table 127: Europe Market Volume (K) (2025-2032) By Types

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 129: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 130: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 131: South America Market Volume (K) (2025-2032) By Country

Table 132: South America Market Volume (K) (2025-2032) By Application

Table 133: South America Market Volume (K) (2025-2032) By Types

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 135: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 136: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 137: Research Programs/Design For This Report

Table 138: Key Data Information From Secondary Sources

Table 139: Key Data Information From Primary Sources

FAQs

1. What is the current Dual-leg Rehabilitation Exoskeleton market size?

The global Dual-leg Rehabilitation Exoskeleton market size surpassed USD 220 million in 2023 and is projected to exceed USD 520 million by 2030, driven by rising stroke and spinal cord injury prevalence plus rapid hospital adoption of robotic gait-training systems.

2. What growth rate is forecast for the Dual-leg Rehabilitation Exoskeleton market?

Analysts forecast a robust 13–15% CAGR through 2030, underpinned by aging populations, expanding reimbursement for robotic therapy, and continuous technology improvements that shorten gait-training sessions and improve neuroplasticity outcomes.

3. Which factors are the key drivers behind market expansion?

Key drivers include the global rise in stroke and SCI cases, mounting evidence that high-dose, task-specific gait training accelerates recovery, supportive reimbursement in the U.S., EU, and Japan, and hospital efforts to reduce therapist physical strain while boosting patient throughput.

4. What challenges currently restrain wider adoption?

High device cost (USD 90k–250k per unit), limited reimbursement in emerging markets, lengthy regulatory pathways, and the need for specialized staff training create adoption hurdles, especially for smaller rehab centers with constrained capital budgets.

5. Which regions lead the Dual-leg Rehabilitation Exoskeleton market?

North America commands ~45% share thanks to VA hospitals and private rehab chains, followed by Europe where Germany, France, and the Netherlands integrate exos into standard stroke protocols; Asia-Pacific is the fastest-growing region, led by China and Japan.

6. Who are the top companies shaping the competitive landscape?

ReWalk, Ekso Bionics, Cyberdyne, Hocoma (DIH), Rex Bionics, and emerging players like Fourier Intelligence and B-Temia dominate via portfolio breadth, FDA/CE clearances, and strategic partnerships with hospitals for outcome-based leasing programs.

7. What future opportunities offer the highest upside?

Portable, lightweight battery models for in-home therapy, pediatric indications, outcome-based leasing to lower hospital CapEx, and integration with AI gait analytics to personalize training dosage represent high-value white spaces in the future outlook.

8. How is technology evolution impacting product performance?

Advances in high-torque flat motors, adaptive AI algorithms that modulate hip-knee assistance in real time, cloud-based therapy analytics, and soft exosuit hybrids collectively reduce device weight, enhance patient comfort, and shorten therapeutic session setup time.

9. What does the regulatory landscape look like for new entrants?

FDA classifies most dual-leg rehab exos as Class II requiring 510(k) clearance focusing on EMC, safety stops, and biocompatibility; EU MDR ups clinical evidence demands, while China NMPA accepts overseas data, accelerating local registrations for proven platforms.

10. How are reimbursement trends influencing purchasing decisions?

In the U.S., CMS Category III CPT codes for robotic gait training create a reimbursement pathway; Germany’s DRG add-on and Japan's robotics subsidy lower provider risk, tipping capital budgets toward exoskeleton acquisition over traditional parallel-bar therapy.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Dual-leg Rehabilitation Exoskeleton Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	560.00 million
Revenue forecast in 2033	2.18 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ekso Bionics; ReWalk Robotics; Parker Hannifin; CYBERDYNE; Rex Bionics; Hocoma; Lockheed Martin; Bionik Laboratories; Honda; SuitX; Myomo; ABLE Human Motion; Interactive Motion Technologies; Autonomyo; B-Temia; ExoAtlet; FREE Bionics; Gogoa Mobility Robots; ZARYA; Panasonic; Alter G; Hyundai
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options